WashU Expert: Incentivizing new uses for off-patent drugs

WashU Expert: Incentivizing new uses for off-patent drugs

Generic medications could be an effective way to improve health outcomes while lowering costs, but the existing drug patent system is poorly designed to motivate such discoveries, says an expert on health law at Washington University in St. Louis.

Does enrolling in medicare HMOs affect mortality?

People who are enrolled in Medicare Choice HMO plans with drug coverage die at about the same rate as those in traditional fee-for-service Medicare plans, but mortality rates for those in Medicare HMO plans without drug coverage are substantially higher. That’s the conclusion of a recent study done by Gautam Gowrisankaran, Ph.D., an assistant professor of economics at the Olin School of Business of Washington University in St. Louis, with University of Minnesota colleague Robert J. Town. The researchers’ estimates imply that a 10-percentage point shift in coverage from fee-for-service to HMO plans without drug coverage could result in 51,000 additional deaths per year among the elderly.

Canadian drug imports won’t bring down the costs of drugs; would likely raise prices

Despite the rejection of a provision to allow prescription drug imports from Canada in the Medicare bill passed by Congress, policymakers are still considering other bills that would allow the drug imports from North of the border. But Jackson Nickerson, a professor of organization and strategy at the Olin School of Business at Washington University in St. Louis, says that allowing the import of drugs from Canada would likely raise prices for both Canadians and U.S. consumers. Nickerson is currently engaged in a major research initiative with the Food & Drug Administration (FDA) and the pharmaceutical industry to improve the manufacturing process for drugs.